Skip to main content
Home

Main navigation

  • About HIPRA

      About HIPRA

    • Discover HIPRA
    • History
    • Sustainability & CSR
    • HIPRA Around the World
  • Animal Health
  • Human Health

      Human Health

    • Products & Services
      • Covid-19 Vaccine
      • Analysis Covid-19
      • GoodGut: digestive health
    • R&D projects
    • News
    • Press
  • Careers
  • Contact us
Career
Search
Search
who we are

Press

07/19/2022 - 10:14

HIPRA’s COVID-19 vaccine induces a good neutralising antibody response against the BA.2, BA.4 and BA.5 subvariants of Omicron

Human
Explore
05/18/2022 - 10:13

HIPRA initiates the first Phase III clinical trial of Covid-19 vaccine in immunocompromised people

Human
Explore
03/29/2022 - 14:02

EMA starts rolling review of Covid-19 HIPRA’s vaccine

Human
Explore
03/16/2022 - 08:45

GoodGut and Vall d'Hebron Barcelona Hospital are studying the implementation of the first non-invasive diagnostic test to detect Irritable Bowel Syndrome

Human
Explore
03/11/2022 - 10:00

AEMPS authorizes Phase IIb second clinical trial of the HIPRA’s vaccine against Covid-19

Human
Explore
02/01/2022 - 15:33

AEMPS authorizes phase III clinical trial of the HIPRA’s vaccine against Covid-19

Human
Explore
  • Load More
Home

Footer second

  • About HIPRA
  • Animal Health
  • Human Health

Footer third

  • Careers
  • Contact us

Footer fourth

  • LinkedIn
  • YouTube

Footer

  • Terms of use
  • Privacy policy
  • Cookies policy